Steven C. Quay - 20 Jan 2026 Form 4 Insider Report for ATOSSA THERAPEUTICS, INC. (ATOS)

Role
President & CEO, Director
Signature
/s/ Steven C. Quay
Issuer symbol
ATOS
Transactions as of
20 Jan 2026
Net transactions value
+$572,850
Form type
4
Filing time
22 Jan 2026, 14:11:52 UTC
Previous filing
22 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
QUAY STEVEN C President & CEO, Director C/O ATOSSA THERAPEUTICS, INC.,, 1448 NW MARKET STREET, SUITE 500, SEATTLE /s/ Steven C. Quay 22 Jan 2026 0001008227
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATOS Common Stock Award $0 +325,203 +2340% $0.000000 339,101 20 Jan 2026 Direct F1
holding ATOS Common Stock 22,254 20 Jan 2026 By Ensisheim Partners, LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATOS Stock Options (right to buy) Award $572,850 +950,000 $0.6030 950,000 20 Jan 2026 Common Stock 950,000 $0.6030 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the acquisition of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest one year from the Transaction date.
F2 Ensisheim Partners, LLC ("Ensisheim") is wholly owned by the Reporting Person and Dr. Shu-Chih Chen. The Reporting Person and Dr. Chen share voting and investment power over the securities held by Ensisheim. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F3 The options shall vest on a quarterly basis over 24 months following January 20, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on January 20, 2026, with an exercise price of $0.603, representing the closing stock price on January 20, 2026.